S1 Fig -

Background Expanding the indication of already approved immuno-oncology drugs presents treatment opportunities for patients but also strains healthcare systems. Cost-based pricing models are discussed as a possibility for cost containment. This study focuses on two drugs, pembrolizumab (Keytruda) and daratumumab (Darzalex), to explore the potential effect of indication broadening on the estimated price when using the cost-based pricing (CBP) model proposed by Uyl-de Groot and Löwenberg (2018). Methods The model was used to calculate cumulative yearly prices, cumulative prices per indication, a... Mehr ...

Volltext
Verfasser: R. J. S. D. Heine
F. W. Thielen
R. H. J. Mathijssen
R. W. F. van Leeuwen
M. G. Franken
C. A. Uyl-de Groot
Dokumenttyp: Image
Erscheinungsdatum: 2024
Schlagwörter: Biotechnology / Ecology / Cancer / Science Policy / Infectious Diseases / Plant Biology / Computational Biology / smaller patient populations / larger patient populations / already approved immuno / sensitivity analysis showed / lower estimates resulted / l &# 246 / deterministic stepwise analysis / eligible patient population / daratumumab per vial / pembrolizumab per vial / daratumumab &# 8217 / xlink \ / > expanding / profit margin contributed / pembrolizumab (&# 8364 / modeled cbps depending / dutch list prices / based pricing models / indication (&# 8364 / assumed lower r / yearly cumulative cost / daratumumab </ p / based pricing model / &# 8364 / > / profit margin / based pricing / scenario analysis / consistently lower / pharmaceutical pricing / cumulative indication / based prices / study focuses / significant influence / significant impact / registered indications / potential effect / ongoing discussions / model proposed / initial years / initial r / indications due / indication expansion / indication broadening
Sprache: unknown
Permalink: https://search.fid-benelux.de/Record/base-26662678
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://doi.org/10.1371/journal.pone.0293264.s003